Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18293252 | 0.82 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL729706 | 0.80 | GRM5 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL20459306 | 0.80 | PDK4 (0.49) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL29233999 | 0.80 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12956427 | 0.79 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL14028045 | 0.79 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL4083087 | 0.79 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL20841532 | 0.79 | GRM1 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL16113049 | 0.79 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL15615840 | 0.79 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | PDK4 1381/4885GRM5 2370/4885GRM1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.